Lilly roughly doubles its Gate Bioscience Sec61 pact, to up to $870M
- Lilly expanded its collaboration with Gate Bioscience to a potential value of up to $870M, from the original 2025 pact worth up to $856M.
- The expansion adds one target, with an option on a second; Gate gets an upfront payment, further payment if a second target is chosen, research funding and milestones.
- Gate's platform works on Sec61, the channel through which secreted and membrane proteins exit the cell; targets and indications are undisclosed.
💡 Points
An expansion rather than a new deal is the real signal: Lilly saw enough from the first target to pay for another. With Pfizer following into Sec61 with Enodia a week later, a small-molecule channel-modulation approach to 'undruggable' secreted proteins is turning into a crowded field. Undisclosed upfront and targets make the economics hard to judge.
Gate CEO sees expanded $870M Lilly pact as 'vote of confidence' ↗